SCHEMBL19985679

SCHEMBL19985679

CC(C)(C)CC(C)(C)c1ccc(Nc2cccc(O)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.54
TSHR P16473 1/20 0.54
SHBG P04278 1/20 0.54
UQCRB P14927 1/20 0.46
ALDH1A1 P00352 2/20 0.44
CYP1A2 P05177 2/20 0.44
MEN1 O00255 2/20 0.44
MAPT P10636 2/20 0.44
KMT2A Q03164 2/20 0.44
USP2 O75604 1/20 0.44
APP P05067 1/20 0.44
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP2C19 P33261 1/20 0.44
SNCA P37840 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324479 0.82 CYP3A4 (0.63) CYP3A4TSHRUQCRBALDH1A1CYP1A2
SCHEMBL8962181 0.82 SHBG (0.52) CYP3A4TSHRSHBGALDH1A1CYP1A2
SCHEMBL411772 0.82 SHBG (0.59) CYP3A4TSHRSHBGALDH1A1MEN1
Resorcinol SCHEMBL8462567 0.80 SHBG (0.78) CYP3A4TSHRSHBGUQCRBALDH1A1
SCHEMBL19985680 0.79 SHBG (0.50) CYP3A4SHBGALDH1A1MEN1MAPT
SCHEMBL1920769 0.78 CYP3A4 (0.86) CYP3A4TSHRALDH1A1CYP1A2MEN1
SCHEMBL8962143 0.77 ALDH1A1 (0.56) CYP3A4SHBGALDH1A1CYP1A2MEN1
SCHEMBL20951293 0.77 SHBG (0.53) CYP3A4TSHRSHBGUQCRBALDH1A1
SCHEMBL3855587 0.77 SHBG (0.59) CYP3A4SHBGUQCRBALDH1A1MEN1
SCHEMBL465314 0.74 SHBG (0.47) CYP3A4TSHRSHBGALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3516019-B1 LUBRICANT COMPOSITIONS STABILIZED BY MIXTURES OF DIARYLAMINE AND HYDROXYDIARYLAMINE ANTIOXIDANTS LANXESS CORP (US) 2023-06-14 EP disclosed
EP-3516020-B1 ALKYLATED 3-HYDROXYDIPHENYLAMINE ANTIOXIDANTS LANXESS CORP (US) 2022-05-25 EP disclosed
US-10723969-B2 Lubricant compositions stabilized by mixtures of diarylamine and hydroxydiarylamine antioxidants LANXESS SOLUTIONS US INC. (US) 2020-07-28 US disclosed
US-10563145-B2 Alkylated 3-hydroxydiphenylamine antioxidants LANXESS SOLUTIONS US INC. (US) 2020-02-18 US disclosed
WO-2018057364-A1 LUBRICANT COMPOSITIONS STABILIZED BY MIXTURES OF DIARYLAMINE AND HYDROXYDIARYLAMINE ANTIOXIDANTS LANXESS SOLUTIONS US INC. (US) 2018-03-29 WO disclosed
WO-2018057366-A1 ALKYLATED 3-HYDROXYDIPHENYLAMINE ANTIOXIDANTS LANXESS SOLUTIONS US INC. (US) 2018-03-29 WO disclosed
US-20180079985-A1 ALKYLATED 3-HYDROXYDIPHENYLAMINE ANTIOXIDANTS LANXESS SOLUTIONS US INC. 2018-03-22 US disclosed
US-20180079985-A1 ALKYLATED 3-HYDROXYDIPHENYLAMINE ANTIOXIDANTS LANXESS SOLUTIONS US INC. 2018-03-22 US disclosed
US-20180079987-A1 LUBRICANT COMPOSITIONS STABILIZED BY MIXTURES OF DIARYLAMINE AND HYDROXYDIARYLAMINE ANTIOXIDANTS LANXESS SOLUTIONS US INC. 2018-03-22 US disclosed
US-20180079987-A1 LUBRICANT COMPOSITIONS STABILIZED BY MIXTURES OF DIARYLAMINE AND HYDROXYDIARYLAMINE ANTIOXIDANTS LANXESS SOLUTIONS US INC. 2018-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180079985-A1 ALKYLATED 3-HYDROXYDIPHENYLAMINE ANTIOXIDANTS GPX4, GSTO1, LPO CYP3A4 478/4885TSHR 4723/4885SHBG 376/4885
US-10563145-B2 Alkylated 3-hydroxydiphenylamine antioxidants GPX4, GSTO1, LPO CYP3A4 478/4885TSHR 4723/4885SHBG 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.